| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ptc Therapeutics, Inc. (PTCT) has 17 insiders with recent SEC Form 4 filings, including 2 buys and 5 sells. PTCT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 394.1K | $32.36M | - | |
| VP | 113.7K | $9.34M | -10,462 | |
| CFO | 90.3K | $7.42M | - | |
| Other | 80.1K | $6.58M | - | |
| VP | 79.1K | $6.50M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 4, 2018 | Utter Christine Marie58 | Principal Financial Officer | Sell | 412 | $17.67 | $7,280.04 | -5.8% | |
| May 23, 2017 | Svoronos Dawn | Director | Buy | 25,000 | $13.49 | $337,230.00 | New | |
| Jan 5, 2017 | Almstead Neil Gregory52 | EVP Research Pharma Ops &Tech | Sell | 78 | $11.82 | $921.96 | -2.8% | |
| Mar 3, 2016 | Rothera Mark | Chief Commercial Officer | Buy | 2,000 | $6.23 | $12,460.00 | +64.0% | |
| Jul 6, 2015 | Southwell David P69 | Director | Sale+OE | 23,604 | $47.52 | $1,121,694.00 | -97.1% | |
| Jun 18, 2015 | Jacobson Allan Steven51 | Director | Sell | 5,000 | $50.13 | $250,650.00 | -42.2% |